The Filing Desk

Tarsus Pharmaceuticals vs Twist Bioscience

Tarsus Pharmaceuticals TARS · Twist Bioscience TWST · Biotechnology

Tarsus Pharmaceuticals reported revenue of $451 million in fiscal 2025, 1.2 times Twist Bioscience's $377 million in fiscal 2025. Tarsus Pharmaceuticals' revenue grew 146.7% in its latest year, and Twist Bioscience's grew 20.3%. Tarsus Pharmaceuticals had an operating margin of -15.7%, against -36.2% at Twist Bioscience. Free cash flow was −$22 million at Tarsus Pharmaceuticals and −$76 million at Twist Bioscience. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.

Side by side

Tarsus PharmaceuticalsTwist Bioscience
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Sep 30, 2025
Revenue$451M$377M
Revenue growth146.7%20.3%
Revenue growth a year, last 5 years—33.1%
Gross margin—50.7%
Operating margin−15.7%−36.2%
Net margin−14.7%−20.6%
Free cash flow−$22M−$76M
Free cash flow margin−4.9%−20.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count11.1%3.1%
Last close$80.28$111.60
P/E at the last close——
Insider trades, last 12 monthssold $20.0 millionsold $126.1 million
Piotroski F-score4 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Tarsus PharmaceuticalsTwist Bioscience
Operating margin
Percent of revenue
Tarsus PharmaceuticalsTwist Bioscience
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Tarsus PharmaceuticalsTwist Bioscience

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Tarsus Pharmaceuticals and Twist Bioscience pages.